{"entity":{"id":"nct05563220","kind":"trial","name":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer","aka":["ELEVATE"],"tldr":"A phase 1/2 trial of Elacestrant, Alpelisib, Everolimus, Ribociclib, Palbociclib and Capivasertib in advanced solid tumours, run by Stemline Therapeutics, Inc., active and no longer recruiting.","summary":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer is a phase 1/2 interventional study registered as NCT05563220 by Stemline Therapeutics, Inc., with 435 participants enrolled, started 2023-01-24 and due to reach its primary completion in 2026-12-27. Interventions recorded: Elacestrant, Alpelisib, Everolimus, Ribociclib, Palbociclib and Capivasertib.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05563220","url":"https://clinicaltrials.gov/study/NCT05563220"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["endocrine-therapy"],"targets":[],"drugs":["elacestrant","alpelisib","everolimus","ribociclib","palbociclib","capivasertib"],"companies":["menarini"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05563220","phase":"1/2","setting":"A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer","sponsor":"Stemline Therapeutics, Inc.","participation":[{"nct":"NCT05563220","source":"https://clinicaltrials.gov/study/NCT05563220","fetchedAt":"2026-10-07T16:53:45.224Z","studySha256":"50d99513a80b6c3778eb5a4b897168bab53e4546e8685725194747a4e1704fd6","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-06-12","leadSponsor":"Stemline Therapeutics, Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":435,"enrolmentType":"ESTIMATED","siteCount":83,"recruitingSiteCount":0,"countries":["Argentina","Australia","Belgium","Brazil","France","Israel","Italy","Luxembourg","South Korea","Spain","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2023-01-24","startedType":"actual","enrolled":435,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05563220/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/"}],"drug":[{"id":"alpelisib","kind":"drug","name":"Alpelisib","route":"/drugs/alpelisib/"},{"id":"capivasertib","kind":"drug","name":"Capivasertib","route":"/drugs/capivasertib/"},{"id":"elacestrant","kind":"drug","name":"Elacestrant","route":"/drugs/elacestrant/"},{"id":"everolimus","kind":"drug","name":"Everolimus","route":"/drugs/everolimus/"},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/"},{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/"}],"company":[{"id":"menarini","kind":"company","name":"Menarini / Stemline","route":"/companies/menarini/"}],"institution":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}]}}